Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06512610
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-16
Brief Title:
ELN 2022 in MENAFC Middle Eastern or North Coast of Africa Patients With Newly AML
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Validation of the Use of the ELN 2022 Risk Stratification System in HLA MENAFC Patients Newly Diagnosed With Acute Myeloid Leukemia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In daily clinical practice 2022 ELN guidelines were used to predict response to conventional treatment and to guide the need for allogenic stem cell transplantation But the team has to underline that ELN guidelines are mainly reflective of relatively young Caucasian patients Few studies have compared 2017 and 2022 ELN in ethnicity cohorts to evaluate the potential prognostic value of this new criteria in these types of population For example with the 2022 ELN guidelines the disease-free surviva and the overall survival of African American 60 yo were not statistically different between intermediate and adverse groups p030 p046 There were not a significant difference between favorable and intermediate groups in DFS p042 p042 respectively in African American and Hispanic patients or in OS p067 in Hispanic patients Is the 2022 ELN applicable to all ethnic subgroups To date no studies have examined and validated its applicability in Middle Eastern or North Coast of Africa MENAFC patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None